CN109675043A - 甲硫氨酸在增敏紫杉醇对乳腺癌治疗效果中的应用 - Google Patents
甲硫氨酸在增敏紫杉醇对乳腺癌治疗效果中的应用 Download PDFInfo
- Publication number
- CN109675043A CN109675043A CN201910158614.5A CN201910158614A CN109675043A CN 109675043 A CN109675043 A CN 109675043A CN 201910158614 A CN201910158614 A CN 201910158614A CN 109675043 A CN109675043 A CN 109675043A
- Authority
- CN
- China
- Prior art keywords
- methionine
- breast cancer
- taxol
- application
- enhancing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930182817 methionine Natural products 0.000 title claims abstract description 44
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title claims abstract description 43
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 31
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 31
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 30
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 18
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 title claims abstract description 15
- 230000035945 sensitivity Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 11
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 22
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 238000010172 mouse model Methods 0.000 abstract description 3
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 230000001665 lethal effect Effects 0.000 abstract 1
- 235000006109 methionine Nutrition 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 108010087230 Sincalide Proteins 0.000 description 6
- 238000010609 cell counting kit-8 assay Methods 0.000 description 6
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 244000050510 Cunninghamia lanceolata Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LURVIJVAAIIEQT-RGMNGODLSA-N [S].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [S].C(CC)N[C@@H](CCO)C(=O)O LURVIJVAAIIEQT-RGMNGODLSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了合用甲硫氨酸对增强紫杉醇治疗乳腺癌药效的应用。通过人源乳腺癌细胞MCF‑7小鼠模型，分别单独给予紫杉醇、甲硫氨酸以及两者联合给药，发现甲硫氨酸自身无显著抗肿瘤效应，但可显著提高紫杉醇对人乳腺癌细胞的抗肿瘤药效作用。在MCF‑7细胞模型中，在培养基中额外补充甲硫氨酸可显著增强紫杉醇对肿瘤细胞的杀伤作用。本发明所述甲硫氨酸可以用于合用以提高紫杉醇化疗疗效，或与紫杉醇共同制备复方增敏药物，以提高紫杉醇对乳腺癌细胞治疗的效果，为临床治疗乳腺癌提供了一个方便、经济、高效的增敏剂。
Description
技术领域
本发明属于肿瘤化疗的增敏药物领域，涉及甲硫氨酸的一种新用途，即甲硫氨酸用于增强紫杉醇治疗乳腺癌药效及其应用。
背景技术
作为严重危害女性身心健康的恶性肿瘤，乳腺癌的发病率在我国所有女性恶性肿瘤中居首位。目前的乳腺癌治疗中，化疗仍然是较为有效且被普遍使用的一种手段，即利用抗癌药物抑制癌细胞分裂，破坏癌细胞的治疗方法，化疗可以有效地降低患者死亡率并延长寿命。但是，化疗药物在临床应用中存在诸多问题，例如多药耐药现象、对正常细胞及组织的毒性等，严重影响了临床化疗的治愈率，据估计有相当一部分乳腺癌患者(高达70％)对于当前的化疗方案响应不佳。紫杉醇(Paclitaxel，PTX)是从裸子植物红豆杉的树皮分离提纯的天然次生代谢产物，经临床验证，具有良好的抗肿瘤作用。因其高效、广谱的特点，紫杉醇从分离至今已被广泛应用于多种恶性肿瘤，也是乳腺癌治疗的一线药物。但不可避免地，紫杉醇在临床使用中也存在很多缺陷，致使疗效降低甚至消失。化疗增敏药物是指自身没有(或很小)抗肿瘤作用，但能够显著增强抗肿瘤药物对肿瘤细胞杀伤作用的化合物(或药物)的总称。国内外研究人员一直致力于研发化疗增敏剂，期望能够提高化疗药物疗效从而延长患者的生命并提高患者生活质量。
甲硫氨酸(Methioine)为构成人体的必需氨基酸之一，可作为氨基酸类药物用于临床，可有效改善肝脏、心肌机能，其临床应用效果可靠且安全。目前还没有甲硫氨酸能有效地提高肿瘤化疗药物敏感性的报道。本发明人研究发现甲硫氨酸可显著增强紫杉醇的抗肿瘤效应。因此，发明人提出，甲硫氨酸与抗肿瘤药物联用可增强化疗药物敏感性，提高临床疗效。
发明内容
本发明以人源乳腺癌细胞MCF-7接种的荷瘤小鼠作为模型动物，通过腹腔注射给予甲硫氨酸联合紫杉醇治疗，测定小鼠肿瘤体积的变化评价甲硫氨酸对紫杉醇的增敏作用，发现甲硫氨酸单用组没有明显的抑瘤作用，紫杉醇单用组呈现出一定的抑瘤作用；与紫杉醇单用相比，紫杉醇与甲硫氨酸联用可显著增强紫杉醇的抗肿瘤药效。此外，本发明以MCF-7为细胞模型，测定细胞存活率评价甲硫氨酸对紫杉醇的增敏作用，发现在培养基中额外补充甲硫氨酸可显著增强紫杉醇对肿瘤细胞的抑制作用。以此为基础，本发明提出甲硫氨酸与紫杉醇联用可应用于乳腺癌的临床治疗。
附图说明
附图1 MCF-7荷瘤小鼠肿瘤大小与形态照片
附图2 MCF-7荷瘤小鼠肿瘤体积变化曲线
附图3 MCF-7荷瘤小鼠肿瘤重量对比图
附图4 MCF-7细胞存活率
附图1-3中，Control为对照组(生理盐水，腹腔注射)，PTX为紫杉醇单用组(5mg/kg/every 3day，腹腔注射)，Methionine为甲硫氨酸补充组(120mg/kg/day，腹腔注射)，PTX+Methionine为紫杉醇联合甲硫氨酸组。*P＜0.05，**P＜0.01vs紫杉醇(PTX)单用组。
附图4中组别分别为：甲硫氨酸(30μg/mL)+PTX(0nM)、甲硫氨酸(30μg/mL)+PTX(10nM)、甲硫氨酸(75μg/mL)+PTX(10nM)、甲硫氨酸(150μg/mL)+PTX(10nM)。*P＜0.05，**P＜0.01vs甲硫氨酸(30μg/mL)+PTX(0nM)组；#P＜0.05，##P＜0.01vs甲硫氨酸(30μg/mL)+PTX(10nM)组。注：细胞培养基中甲硫氨酸本底含量即为30μg/mL。
具体实施方式
本发明通过下面的实施例进行详细的解释，但并不意味着本发明仅限于此。
细胞来源与培养：人乳腺癌细胞MCF-7购于中国医学科学院天津血液病研究所(天津，中国)，细胞培养在37℃，含5％CO2的环境中，培养液为RPMI1640培养基，含10％胎牛血清(FBS)，以及链霉素100mg/L，青霉素62.5mg/L。细胞生长于10cm培养皿中，2～3天更换培养基一次，待细胞生长至90％融合时进行传代。
动物来源与饲养：采用Balb/c-nu/nu小鼠(雌性，由南京大学模式动物研究所提供，周龄4～6，体重20±2g)进行实验。在标准饲养环境下(自由饮食与饮水，昼夜交替，各12小时)，适应性饲养一周。动物饲养和全部实验于中国药科大学SPF级小鼠饲养室完成。
MCF-7荷瘤小鼠模型的建立：将MCF-7细胞消化，无菌PBS重悬后，在小鼠上肢腋下皮下注射入体内进行接种，每只小鼠接种106～107个/0.2mL，每日观察老鼠状态并测量瘤体积。1～2周后，选取出接种成功的荷瘤小鼠(n＝5)，待瘤体达100mm3后，将荷瘤小鼠按体重随机分为4组，开始按照需要给药处理。
MCF-7荷瘤小鼠实验设计和分组如下：Control组(生理盐水，腹腔注射)，PTX组(5mg/kg/every 3day，腹腔注射)，Methionine组(120mg/kg/day，腹腔注射)，PTX+Methionine组。每隔两或三日测量小鼠体重及瘤体的长径和短径，计算瘤体积并绘制曲线。给药3周之后，处死动物，迅速取出肿瘤组织，清洗拭干后，称重并拍照。
CCK-8法测定MCF-7细胞活性实验设计和分组：取对数生长期的MCF-7细胞，用0.1％胰酶消化细胞，以5000cell/孔接种于96孔培养板中。24小时后，待细胞基本贴壁后更换为含药培养基。给药方案如下：甲硫氨酸(30μg/mL)+PTX(0nM)(对照组)、甲硫氨酸(30μg/mL)+PTX(10nM)、甲硫氨酸(75μg/mL)+PTX(10nM)、甲硫氨酸(150μg/mL)+PTX(10nM)。37℃孵育48小时后，向各孔中加入10μL CCK-8(凯基生物)检测溶液，37℃下孵育1～4小时，摇床上温柔混匀，酶标仪在450nm波长处检测每孔的吸光度。
细胞存活率(％)＝[(As-Ab)/(Ac-Ab)]×100；
As＝实验孔吸光度(含有细胞，培养基，CCK-8和受试化合物的孔的吸光度)；
Ab＝空白孔吸光度(含有培养基和CCK-8的孔的吸光度)；
Ac＝对照孔吸光度(含有细胞，培养基和CCK-8的孔的吸光度)。
测定结果表明，在MCF-7荷瘤小鼠模型中，甲硫氨酸联合紫杉醇给药组小鼠的肿瘤体积有非常显著的变小趋势；CCK-8结果显示，补充甲硫氨酸显著增强紫杉醇对肿瘤细胞的抑制作用。由此可见，紫杉醇合并甲硫氨酸补充能够显著抑制肿瘤细胞的增长，即甲硫氨酸可显著增强紫杉醇的抗肿瘤药效。
Claims (6)
1.甲硫氨酸在制备用于增强抗肿瘤药治疗效果新药物的应用。
2.根据权利要求1所述甲硫氨酸在制备用于增强抗肿瘤药治疗效果新药物的应用，其特征在于：所述抗肿瘤增效药物为紫杉醇。
3.根据权利要求2所述甲硫氨酸在制备用于增强抗肿瘤治疗效果新药物的应用，其特征在于：所述抗肿瘤增效药物除了紫杉醇外，还可以是其它抗肿瘤药物，如多西他赛、阿霉素、表阿霉素等抗肿瘤药物。
4.根据权利要求3所述甲硫氨酸在制备用于增强抗肿瘤治疗效果新药物的应用，其特征在于：所述肿瘤为乳腺癌。
5.根据权利要求4所述甲硫氨酸在制备用于增强抗肿瘤治疗乳腺癌效果新药物的应用，其特征在于：所述肿瘤除乳腺癌外，还可以是非小细胞肺癌、肝癌、结肠癌、胃癌、急性或慢性粒性白血病等肿瘤。
6.根据权利要求5所述甲硫氨酸在制备用于增强抗肿瘤治疗效果新药物的应用，其特征在于：甲硫氨酸可以作为单独成分与抗肿瘤药物分开使用，或将甲硫氨酸与抗肿瘤药物合并使用，或2者以一定配比制备成为复方药物使用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910158614.5A CN109675043A (zh) | 2019-02-28 | 2019-02-28 | 甲硫氨酸在增敏紫杉醇对乳腺癌治疗效果中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910158614.5A CN109675043A (zh) | 2019-02-28 | 2019-02-28 | 甲硫氨酸在增敏紫杉醇对乳腺癌治疗效果中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109675043A true CN109675043A (zh) | 2019-04-26 |
Family
ID=66196204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910158614.5A Pending CN109675043A (zh) | 2019-02-28 | 2019-02-28 | 甲硫氨酸在增敏紫杉醇对乳腺癌治疗效果中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109675043A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577058A (zh) * | 2021-09-03 | 2021-11-02 | 丽水市中心医院 | 吡喃酮化合物在制备肺癌化疗增敏药物中的应用及药物 |
| CN115227688A (zh) * | 2022-07-06 | 2022-10-25 | 上海纳米技术及应用国家工程研究中心有限公司 | 双硫仑在增敏紫杉醇对肺癌治疗效果中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040850A (zh) * | 2013-01-22 | 2013-04-17 | 中国药科大学 | 蛋氨酸-抗肿瘤复合药物及其制备方法 |
-
2019
- 2019-02-28 CN CN201910158614.5A patent/CN109675043A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040850A (zh) * | 2013-01-22 | 2013-04-17 | 中国药科大学 | 蛋氨酸-抗肿瘤复合药物及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| KYONGSHIN CHO等: "Lipotropes enhance the anti-proliferative effect of chemotherapeutic drugs in MCF-7 human breast cancer cells", 《ONCOLOGY REPORTS》 * |
| 刘冀红等: "右旋甲硫氨酸与紫杉醇联合应用治疗胃癌", 《肠外与肠内营养》 * |
| 李艳等: "同型半胱氨酸和D-二聚体在非小细胞肺癌外周血中的水平及其相关性研究", 《浙江临床医学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577058A (zh) * | 2021-09-03 | 2021-11-02 | 丽水市中心医院 | 吡喃酮化合物在制备肺癌化疗增敏药物中的应用及药物 |
| CN113577058B (zh) * | 2021-09-03 | 2023-03-14 | 丽水市中心医院 | 吡喃酮化合物在制备肺癌化疗增敏药物中的应用及药物 |
| CN115227688A (zh) * | 2022-07-06 | 2022-10-25 | 上海纳米技术及应用国家工程研究中心有限公司 | 双硫仑在增敏紫杉醇对肺癌治疗效果中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hou et al. | In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment | |
| CN102552908B (zh) | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
| CN109985237A (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| CN109675043A (zh) | 甲硫氨酸在增敏紫杉醇对乳腺癌治疗效果中的应用 | |
| EP1784172A2 (en) | Cancer chemotherapy | |
| CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 | |
| CN105476996A (zh) | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 | |
| CN111888370A (zh) | 一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 | |
| CN101167741B (zh) | 莱菔硫烷和铂类药的抗癌联合制剂 | |
| CN101485665B (zh) | 葫芦素的医药用途 | |
| CN101229175A (zh) | 一对原人参二醇衍生物和它们混合体的医药用途 | |
| CN110613716B (zh) | 一种用于治疗癌症的药物组合物及其应用 | |
| CN111494385B (zh) | 一种治疗卵巢癌的药物及其制备方法和用途 | |
| CN108283645A (zh) | 胱氨酸在增敏阿霉素对乳腺癌治疗效果中的应用 | |
| CN104623215B (zh) | 一种抗肿瘤的药物组合物 | |
| CN103655559A (zh) | 角蒿酯碱类化合物在制备抗乳腺癌药物中的应用 | |
| KR20210150470A (ko) | A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용 | |
| CN107441076B (zh) | 一种治疗癌症的联合用药物 | |
| CN110403924A (zh) | 一种治疗皮肤黑色素瘤的药物组合物及其制备方法 | |
| CN102232957B (zh) | 3-乙酰氧基-8,24-羊毛甾二烯-21-酸在制备预防、治疗肝癌或乳腺癌药物中的用途 | |
| CN112618569A (zh) | 一种用于治疗尿路上皮癌的药物 | |
| CN107412736B (zh) | 一种抗肿瘤联合用药物及其在制备抗癌药物中的用途 | |
| CN110693903B (zh) | 一种治疗急性单核细胞白血病的药物及三氧化二砷和双氢青蒿素的应用 | |
| CN109432113A (zh) | 槐糖脂与依托泊苷的联合给药在肿瘤治疗领域中的应用 | |
| CN110559287A (zh) | 一种用于治疗癌症的药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190426 |
|
| WD01 | Invention patent application deemed withdrawn after publication |